Response to the drug in progressive forms of multiple sclerosis appears to be driven by effects in primary, rather than secondary, progressive disease. Differences in the pace of atrophy progression may explain.
Neurologist Robert Fox, MD, is the 2018 Sones Innovation Award honoree for leading pioneering advancements in brain imaging and treatment of the challenging progressive form of multiple sclerosis.
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?